

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application. Kindly cancel claims 1-21 and 29-64 and withdraw claim 24 as drawn to a non-elected species as follows:

**Listing of Claims:**

1.-21. (Cancelled)

22. (Original) A method of treating vasospasm in a subject needing such treatment comprising the step of:

applying to the region of the subject's tissue requiring treatment an effective amount of a semi-solid composition, the composition comprising:

a vasoactive prostaglandin;

a penetration enhancer;

a polymer thickener selected from the group consisting of a shear-thinning polysaccharide gum and a shear-thinning polyacrylic acid polymer;

a lipophilic component that is selected from the group consisting of an aliphatic C<sub>1</sub> to C<sub>8</sub> alcohol, an aliphatic C<sub>8</sub> to C<sub>30</sub> ester, a liquid polyol and a mixture thereof; water and

a buffer system that provides a buffered pH value for said composition in the range of about 3 to about 7.4.

23. (Original) The method of claim 22 wherein the tissue is skin.

24. (Withdrawn) The method of claim 22 wherein the tissue is vascular extima.

25. (Original) The method of claim 22 wherein the vasoactive prostaglandin is selected from the group consisting of prostaglandin E<sub>1</sub>, prostaglandin E<sub>2</sub>, a pharmaceutically acceptable salt thereof, a lower alkyl ester thereof and a mixture thereof.

26. (Original) The method of claim 22 wherein the penetration enhancer is selected from the group consisting of an alkyl-N-substituted amino) alkanoate, an alkyl-2-(N,N-disubstituted amino) alkanoate, an (N-substituted amino) alkanol alkanoate, an (N,N-disubstituted amino) alkanol alkanoate, a pharmaceutically acceptable salt thereof and a mixture thereof.

27. (Original) The method of claim 22 wherein the penetration enhancer is dodecyl 2-(N,N-dimethylamino)-propionate or a pharmaceutically acceptable salt thereof.

28. (Original) The method of claim 22 wherein the lipophilic component comprises at least one aliphatic C<sub>8</sub> to C<sub>30</sub> ester.

29 – 64 (Cancelled)